FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a crystalline form of 6-methyl-2-ethylpyridin-3-ol malate characterized by the positions of the peaks in the powder X-ray pattern obtained using Cu(Kα)-radiation, 2θ, deg: 11.0± 0.2, 17.2± 0.2, 24.7± 0.2 and 26.0± 0.2. The invention also relates to a pharmaceutical composition and a medicinal product containing a crystalline form of 6-methyl-2-ethylpyridin-3-ol malate, as well as their use for the symptomatic treatment of neurological and mental diseases or disorders, circulatory disorders, as well as for improving cognitive abilities.
EFFECT: reduced hygroscopicity while maintaining good solubility and high stability of 6-methyl-2-ethylpyridin-3-ol salt, therapeutic efficacy for symptomatic treatment of neurological and mental diseases or disorders, circulatory disorders and improvement of cognitive abilities.
13 cl, 2 dwg, 3 tbl, 10 ex
